StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTI) shareholders

KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
$0.04−0.01 (-20.00%)

Close on Nov 9, 2026Market cap $1.16KP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
22M
Shares held, 13F filers
Institutional holders
96
34 new, 14 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 21 sales
Net sold $351.42K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more
2,302,5049.90%13G (passive) amendmentJun 30, 2026
Rajeev Shah
Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more
2,078,9139.90%13G (passive)Mar 26, 2026
Affinity Asset Advisors, LLC
Joint filing with Michael Cho (8.60%)
2,073,5178.60%13G (passive) amendmentMar 31, 2026
Commodore Capital Master LP
Joint filing with Commodore Capital LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more
1,950,0009.90%13G (passive)Mar 26, 2026
Michael Cho
Joint filing with Affinity Asset Advisors, LLC (8.60%)
1,713,0928.60%13G (passive) amendmentJan 22, 2026
Opaleye Management Inc.
Joint filing with Opaleye, L.P. (9.48%), James Silverman (9.48%)
1,569,0029.48%13G (passive)Oct 10, 2025
T. Rowe Price Investment Management, Inc.1,539,1476.60%13G (passive) amendmentMay 31, 2026
Robert Atchinson
Joint filing with Adage Capital Management, L.P. (6.78%), Phillip Gross (6.78%)
1,536,7366.78%13G (passive) amendmentJun 30, 2026
Israel A. Englander
Joint filing with Integrated Core Strategies (US) LLC (5.70%), Millennium Management LLC (5.70%) and 1 more
1,297,2975.70%13G (passive)Aug 31, 2026
BlackRock, Inc.1,266,0845.60%13G (passive)Jun 30, 2026
Affinity Healthcare Fund, LP
Joint filing with Affinity Asset Advisors, LLC (7.83%)
664,2247.83%13G (passive)Apr 3, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of KPTIValueChange% of portfolio
Ra Capital Management, L.P.1,917,354–$18.73M–0.16%
Adage Capital Partners Gp, L.L.C.1,521,322–$14.86M−285,0000.02%
Acorn Capital Advisors, LLC1,518,113–$14.83M+1,230,2874.05%
Goldman Sachs Group Inc1,424,658–$13.92M+477,0790.00%
BlackRock, Inc.1,418,799–$13.86M+1,173,9000.00%
Kalehua Capital Management LLC1,371,288–$13.40MNew4.27%
Vanguard Capital Management LLC958,979–$9.37M+219,2340.00%
Catalio Capital Management, LP940,855–$9.19M+43,1461.73%
Avidity Partners Management LP924,487–$9.03M−2,9951.45%
T. Rowe Price Investment Management, Inc.786,309–$7.68M−755,7810.01%
Two Sigma Investments, LP695,264–$6.79M+544,0320.00%
NEA Management Company, LLC576,780–$5.64MNew0.35%
Geode Capital Management, LLC531,231–$5.19M+325,0980.00%
Ghisallo Capital Management LLC500,000–$4.89MNew0.10%
Soleus Capital Management, L.P.440,000–$4.30M–0.15%
UBS Group AG353,545–$3.45M+159,5280.00%
State Street Corp325,991–$3.18M+245,2490.00%
Affinity Asset Advisors, LLC312,500–$3.05M−187,5000.14%
Brevan Howard Capital Management LP309,817–$3.03M+97,4500.02%
Millennium Management LLC305,676–$2.99M−114,8950.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 20269622M34 / 3014 / 149M5M
Q1 20267618M24 / 3110 / 1512M3M
Q4 20256910M27 / 195 / 97M0M
Q3 2025513M7 / 720 / 50M2M
Q2 2025494M12 / 126 / 101M0M
Q1 2025473M47 / 00 / 03M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

66 funds held KPTI in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of KPTIValue% of fundAs of
Vanguard Total Stock Market Index Fund677,729–$6.62M0.00%Jun 30, 2026
iShares Russell 2000 ETF490,317–$4.79M0.01%Jun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.435,070–$4.25M0.04%Jun 30, 2026
Vanguard Extended Market Index Fund263,084–$2.57M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund216,009–$414.74K0.00%Jul 31, 2026
iShares Russell 2000 Value ETF153,539–$1.50M0.01%Jun 30, 2026
Fidelity Extended Market Index Fund94,581–$860.69K0.00%May 31, 2026
iShares Russell 2000 Growth ETF81,441–$795.68K0.01%Jun 30, 2026
iShares Micro-Cap ETF66,938–$653.98K0.04%Jun 30, 2026
Ultra-Small Company Fund49,873–$487.26K0.49%Jun 30, 2026
Schwab Small-Cap Index Fund48,520–$93.16K0.00%Jul 31, 2026
Master Small Cap Index Series37,232–$363.76K0.01%Jun 30, 2026
Fidelity Total Market Index Fund34,152–$310.78K0.00%May 31, 2026
Nomura Healthcare Fund33,333–$325.66K0.04%Jun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF32,185–$61.80K0.00%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Richard A. PaulsonPresident and CEO, Director269,747May 15, 2026
Kristin AbateChief Accounting Officer18,616Oct 19, 2026
Stuart PoultonEVP, Chief Development Officer94,632Jul 30, 2026
Reshma RangwalaEVP & Chief Medical Officer56,829May 15, 2026
Sohanya Roshan ChengEVP & Chief Commercial Officer107,940May 15, 2026
Michael ManoEVP, CLO&Secretary94,398May 15, 2026
Lori MacomberEVP, CFO & Treasurer85,105Feb 4, 2026
Christy J. OligerDirector15,508May 26, 2026
Chen SchorDirector15,508May 26, 2026
Barry E. GreeneDirector16,415May 26, 2026
Garen G. BohlinDirector18,517May 26, 2026
Deepika PakianathanDirector15,508May 26, 2026
Zhen SuDirector15,508May 26, 2026
Mansoor Raza MirzaDirector17,121May 29, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Kristin Abate
Chief Accounting Officer
Oct 16, 2026Sale−4,788$0.34$1.65K18,616
Kristin Abate
Chief Accounting Officer
Oct 1, 2026Sale−378$1.19$45023,404
Kristin Abate
Chief Accounting Officer
Sep 1, 2026Sale−19$2.02$3823,782
Stuart Poulton
EVP, Chief Development Officer
Jul 28, 2026Sale−189$7.10$1.34K94,632
Christy J. Oliger
Director
May 21, 2026Award+15,508––15,508
Garen G. Bohlin
Director
May 21, 2026Award+15,508––18,517
Zhen Su
Director
May 21, 2026Award+15,508––15,508
Chen Schor
Director
May 21, 2026Award+15,508––15,508
Deepika Pakianathan
Director
May 21, 2026Award+15,508––15,508
Barry E. Greene
Director
May 21, 2026Award+15,508––16,415
Stuart Poulton
EVP, Chief Development Officer
May 14, 2026Sale−403$9.50$3.83K94,821
Kristin Abate
Chief Accounting Officer
May 14, 2026Sale−53$9.50$50423,801
Michael Mano
EVP, CLO&Secretary
May 14, 2026Sale−266$9.50$2.53K94,398
Richard A. Paulson
President and CEO, Director
May 14, 2026Sale−2,203$9.50$20.93K269,747
Reshma Rangwala
EVP & Chief Medical Officer
May 14, 2026Sale−408$9.50$3.88K56,829
Sohanya Roshan Cheng
EVP & Chief Commercial Officer
May 14, 2026Sale−324$9.50$3.08K107,940
Stuart Poulton
EVP, Chief Development Officer
May 13, 2026Award+896––95,224
Kristin Abate
Chief Accounting Officer
May 13, 2026Award+121––23,854
Michael Mano
EVP, CLO&Secretary
May 13, 2026Award+700––94,664
Richard A. Paulson
President and CEO, Director
May 13, 2026Award+4,920––271,950
Reshma Rangwala
EVP & Chief Medical Officer
May 13, 2026Award+947––57,237
Sohanya Roshan Cheng
EVP & Chief Commercial Officer
May 13, 2026Award+947––108,264
Reshma Rangwala
EVP & Chief Medical Officer
Apr 21, 2026Sale−449$8.94$4.01K56,290
Stuart Poulton
EVP, Chief Development Officer
Mar 2, 2026Sale−5,101$9.41$48.00K94,328
Kristin Abate
Chief Accounting Officer
Mar 2, 2026Sale−559$9.41$5.26K22,063
Michael Mano
EVP, CLO&Secretary
Mar 2, 2026Sale−3,526$9.41$33.18K93,964
Richard A. Paulson
President and CEO, Director
Mar 2, 2026Sale−12,361$9.41$116.32K267,030
Sohanya Roshan Cheng
EVP & Chief Commercial Officer
Mar 2, 2026Sale−4,604$9.41$43.32K107,317
Reshma Rangwala
EVP & Chief Medical Officer
Mar 2, 2026Sale−5,066$9.41$47.67K56,739
Stuart Poulton
EVP, Chief Development Officer
Feb 17, 2026Sale−378$8.63$3.26K99,429
Richard A. Paulson
President and CEO, Director
Feb 5, 2026Award+81,060––279,391
Lori Macomber
EVP, CFO & Treasurer
Feb 3, 2026Sale−1,626$6.30$10.24K85,105
Lori Macomber
EVP, CFO & Treasurer
Jan 31, 2026Award+32,415––86,731
Sohanya Roshan Cheng
EVP & Chief Commercial Officer
Jan 31, 2026Award+32,415––111,921
Michael Mano
EVP, CLO&Secretary
Jan 31, 2026Award+32,415––97,490
Stuart Poulton
EVP, Chief Development Officer
Jan 31, 2026Award+32,415––99,807
Reshma Rangwala
EVP & Chief Medical Officer
Jan 31, 2026Award+32,415––61,805
Kristin Abate
Chief Accounting Officer
Jan 28, 2026Sale−50$7.03$35222,622
Kristin Abate
Chief Accounting Officer
Jan 27, 2026Award+92––22,672
Kristin Abate
Chief Accounting Officer
Jan 21, 2026Sale−265$5.96$1.58K22,580
Richard A. Paulson
President and CEO, Director
Oct 15, 2025Award+114,285––198,331
Michael Mano
SVP, General Counsel&Secretary
Oct 15, 2025Award+43,650––65,075
Lori Macomber
EVP, CFO & Treasurer
Oct 15, 2025Award+43,650––54,316
Kristin Abate
Chief Accounting Officer
Oct 15, 2025Award+12,799––22,845
Stuart Poulton
EVP, Chief Development Officer
Oct 15, 2025Award+39,682––67,392
Sohanya Roshan Cheng
EVP & Chief Commercial Officer
Oct 15, 2025Award+43,650––79,506
Kristin Abate
Chief Accounting Officer
Oct 1, 2025Sale−362$6.30$2.28K10,046
Sohanya Roshan Cheng
EVP & Chief Commercial Officer
Sep 15, 2025Sale−325$6.43$2.09K35,856
Richard A. Paulson
President and CEO, Director
Sep 15, 2025Sale−1,257$6.43$8.08K84,046
Michael Mano
SVP, General Counsel&Secretary
Sep 15, 2025Sale−234$6.43$1.50K21,425
Kristin Abate
Chief Accounting Officer
Sep 15, 2025Sale−23$6.43$14810,408
Stuart Poulton
EVP, Chief Development Officer
Sep 15, 2025Sale−401$6.43$2.58K27,710
Reshma Rangwala
EVP & Chief Medical Officer
Sep 15, 2025Sale−408$6.43$2.62K29,390
Sohanya Roshan Cheng
EVP & Chief Commercial Officer
Sep 12, 2025Award+945––36,181
Richard A. Paulson
President and CEO, Director
Sep 12, 2025Award+2,800––85,303
Michael Mano
SVP, General Counsel&Secretary
Sep 12, 2025Award+612––21,659
Kristin Abate
Chief Accounting Officer
Sep 12, 2025Award+46––10,431
Stuart Poulton
EVP, Chief Development Officer
Sep 12, 2025Award+888––28,111
Reshma Rangwala
EVP & Chief Medical Officer
Sep 12, 2025Award+945––29,798
Kristin Abate
Chief Accounting Officer
Sep 3, 2025Sale−12$6.78$819,463

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
8M shares short
Days to cover
1.1
At 8M shares a day
Change since last report
+13.3%
From 7M shares
Short volume, 20 days
52.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Karyopharm Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 144,292 shares on Sep 3, 2026 over the last 90 days.

See a number that looks wrong?